Biofusion launches Genophrenix
Second new spin-out company to focus on developing targets and compounds to treat schizophrenia
The genetic basis of schizophrenia is still poorly understood and consequently the understanding of the mode of action of currently prescribed drugs for schizophrenia is far from complete. As a result many of the drugs which are currently used to treat schizophrenia cause unwanted and potentially severe side-effects and lack acceptable efficacy. These limitations often lead to patients discontinuing therapy, clearly a very unsatisfactory outcome. It is clear that a more precise understanding of the causes of schizophrenia are required if new improved therapeutics, that are clearly needed to treat this disease, are to be developed.
Genophrenix believes that their discovery of proteins thought to play a role in the development of schizophrenia, will allow it to become an important partner to the pharmaceutical industry in developing new therapies and drug targets for the treatment of schizophrenia. The Company will seek to consolidate existing findings in the field of schizophrenia in order to add value to the intellectual property that it has already generated. Genophrenix aims to develop packages of novel proprietary therapeutic targets and compounds which can be licensed to major global pharmaceutical companies focused on developing new treatments for schizophrenia.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.